The prognostic value of long noncoding RNAs in prostate cancer: a systematic review and meta-analysis

Weijie Ma, Xi Chen, Lu Ding, Jianhong Ma, Wei Jing, Tian Lan, Haseeb Sattar, Yongchang Wei, Fuling Zhou and Yufeng Yuan _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:57755-57765. https://doi.org/10.18632/oncotarget.17645

Metrics: PDF 2165 views  |   HTML 3603 views  |   ?  


Weijie Ma1,*, Xi Chen1,*, Lu Ding2,*, Jianhong Ma3,*, Wei Jing4, Tian Lan1, Haseeb Sattar5, Yongchang Wei6, Fuling Zhou3 and Yufeng Yuan1

1Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China

2Department of Clinical Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China

3Department of Gynaecology and Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, China

4Department of Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, China

5Department of Clinical Pharmacy, Wuhan Union Hospital, Affiliated Hospital, Tongji Medical College, Huazhong University of Science And Technology, Wuhan, China

6Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China

*These authors have contributed equally to this work

Correspondence to:

Yufeng Yuan, email: [email protected]

Keywords: long non-coding RNA, prognosis, survival, clinicopathology, prostate cancer

Received: March 06, 2017     Accepted: April 25, 2017     Published: May 07, 2017


The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, we conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into our analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS) (HR = 1.55, 95%CI: 1.01–2.37, P < 0.05), recurrence free survival (RSF) (HR = 3.07, 95%CI: 1.07–8.86, P < 0.05) and progression free survival (PFS) (HR = 2.34, 95%CI: 1.94–2.83, P < 0.001) in PCa patients. LncRNAs expression level was correlated with several vital clinical features, like tumor size (HR = 0.52, 95%CI: 0.28–0.95, P = 0.03), distance metastasis (HR = 4.55, 95%CI: 2.26–9.15, P < 0.0001) and histological grade (HR = 6.23, 95% CI: 3.29–11.82, P < 0.00001). Besides, down-regulation of PCAT14 was associated with the prognosis of PCa [over survival (HR = 0.77, 95%CI: 0.63–0.95, P = 0.01), BCR-FS (HR = 0.61, 95%CI: 0.48–0.79, P = 0.0001), prostate cancer-specific survival (HR = 0.64, 95%CI: 0.48–0.85, P = 0.002) and metastasis-free survival (HR = 0.61, 95%CI: 0.50-0.74, P < 0.00001)]. And, the increased SChLAP1 expression could imply the worse BCR-FS (HR = 2.54, 95%CI: 1.82-3.56, P < 0.00001) and correlate with Gleason score (< 7 vs ≥ 7) (OR = 4.11, 95% CI: 1.94-8.70, P = 0.0002). Conclusively, our present work demonstrated that LncRNAs transcription level might be potential prognostic markers in PCa.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17645